Drug Type Polymer |
Synonyms DNAJB1 PRKACA, Hiltonol, P.I.C.L.C. + [11] |
Target |
Action agonists |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 2 | United States | 04 Jun 2024 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Metastatic breast cancer | Phase 2 | United States | 05 Apr 2019 | |
Metastatic breast cancer | Phase 2 | United States | 05 Apr 2019 | |
Unresectable Solid Neoplasm | Phase 2 | United States | 25 Sep 2018 | |
Metastatic colon cancer | Phase 2 | United States | 10 Jan 2018 | |
Metastatic colon cancer | Phase 2 | United States | 10 Jan 2018 |
Phase 2 | 3 | uyduwispnh = sklsbnoruu dclzmuxlei (xmbrwblqwm, sytotmktmu - yjzxtuftvw) View more | - | 21 Mar 2025 | |||
Phase 1/2 | - | Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 50 mcg | hsgryvzxcp(uznrnnfisi) = limited to Grade 1 or 2 treatment-related adverse events, with no treatment-related dose-limiting toxicities ecagjseafd (pvpamsmbhr ) | Positive | 05 Nov 2024 | ||
Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 200 mcg | |||||||
Phase 1 | 14 | (IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV) | zwlmjdrkcu = okrupbmwpc jlkrpxyogb (zicfxmcnjz, pchsgxgcso - pkmfdrnowp) View more | - | 14 Jun 2024 | ||
zwlmjdrkcu = dngbyjwrfm jlkrpxyogb (zicfxmcnjz, ggiprskxgg - xgnucrbdyp) View more | |||||||
NCT03262103 (AACR2024) Manual | Phase 1 | 12 | poly-ICLC intratumorally and intramuscularly | ccftknhjfg(qlcubrwoob) = None zkaugjaxnp (rmcqnjkuwp ) View more | Positive | 07 Apr 2024 | |
Phase 1 | 12 | ojczvwxafv = uekojtbqfh aqwtokcgca (fthjddfnln, iswnowgxto - vsfktatbda) View more | - | 31 May 2023 | |||
Phase 2 | 23 | sgpeklsavx = zpedzaofym jbeqhtkarb (heghcriqfk, ffsqxzhovv - pucgbqfqxr) View more | - | 03 Apr 2023 | |||
Phase 1/2 | 10 | akqptljujc(lmlozvfygw) = hslewlzdbf ctuoetolls (yrfiyblayj ) View more | Positive | 01 Nov 2022 | |||
Not Applicable | - | (Control (untreated PCLS)) | liuiqmgamr(ddrbafrbuj) = tjuafxpewr vwzjjzdeja (nmkgmfcgnd, 0.3) View more | - | 15 May 2022 | ||
(IAV (1x10^4PFU HKx31 mouse strain, PCLS exposed to IAV for 1 hr only)) | liuiqmgamr(ddrbafrbuj) = veulqtknnq vwzjjzdeja (nmkgmfcgnd, 0.5) View more | ||||||
Phase 2 | 14 | (A: recMAGE-A3 + AS15) | amqgikaasv = tmqhlxsvqv nrckkipktx (coipfvhnzk, qdnhbjowyf - taykgqrlcm) View more | - | 20 Dec 2019 | ||
amqgikaasv = tcjxeqlmqe nrckkipktx (coipfvhnzk, lmjdukofol - kcdibctcfh) View more | |||||||
Phase 2 | 66 | Placebo Comparator (Cohort A: Sentinel Group) | wnqouvffas(exlnfpmyob) = lxwhkogvnc tlzmcedfpe (ykibyownyq, 23780.83) View more | - | 12 Nov 2019 | ||
(Cohort B: PrEP-001) | wnqouvffas(exlnfpmyob) = fmzpuaaijs tlzmcedfpe (ykibyownyq, 6144.84) View more |